PT  - JOURNAL ARTICLE
AU  - AKITO HATA
AU  - NOBUYUKI KATAKAMI
AU  - SHIGEKI NANJO
AU  - CHIYUKI OKUDA
AU  - REIKO KAJI
AU  - YUKIHIRO IMAI
TI  - Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures
DP  - 2017 May 01
TA  - In Vivo
PG  - 475--479
VI  - 31
IP  - 3
4099  - http://iv.iiarjournals.org/content/31/3/475.short
4100  - http://iv.iiarjournals.org/content/31/3/475.full
SO  - In Vivo2017 May 01; 31
AB  - Aim: The aim of the present study was to compare successful rate, failure reasons, and complications among procedures of histological rebiopsy. Patients and Methods: We retrospectively reviewed medical records of histologically rebiopsied cases with non-small cell lung cancer. Results: One hundred and eleven histological rebiopsies were performed in: 86 (77%) lung; 11 (10%) lymph node; 5 (5%) pleura; 4 (4%) liver; 2 (2%) muscle; 2 (2%) adrenal gland; and 1 (1%) rib. Successful rate by computed tomography-guided biopsy (CTGB), transbronchial biopsy (TBB), and ultrasound-guided biopsy were 86% (48/56), 90% (28/31), and 100% (24/24), respectively. Reasons for rebiopsy failure by CTGB were no/insufficient malignant cells (n=5) and pneumothorax (n=3), and those by TBB were no/insufficient malignant cells (n=2) and bleeding (n=1). Severe complications (≥grade 3): one grade 3 pneumothorax and one grade 4 air embolization were observed in two (2%, 2/111) cases receiving CTGB. Conclusion: Rebiopsy of histological samples can be highly successful and feasible by optimal procedural selection.